What question did this study set out to answer?

This research aims to evaluate how generalizable AI can distinguish between TROP-2 and cMET phenotypes in non-small cell lung cancer (NSCLC).

April 10, 2026Open Access

ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes

Key Points

This research aims to evaluate how generalizable AI can distinguish between TROP-2 and cMET phenotypes in non-small cell lung cancer (NSCLC).
Utilized foundation model-based scoring for biomarker quantification.
Analyzed TME phenotypes to categorize as TROP-2-high immune-deserted and cMET-high immune-active.
Evaluated therapeutic implications of identified phenotypes.
AI effectively distinguished TROP-2 and cMET phenotypes in NSCLC.
Identified therapeutic combinations involving ADCs and immunotherapies or kinase inhibitors.
Results demonstrate significant variability in immune activity between the two phenotypes.

Abstract

Foundation model-based scoring produces expert-level, scalable biomarker quantification. The resulting TME phenotypes - TROP-2-high immune-deserted vs cMET-high, immune-active - reveal therapeutic implications for combining ADCs with immunotherapies or kinase inhibitors.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Philipp Anders

Marvin Sextro

Katja Lingelbach

Journals

Clinical Cancer Research

Actions

Institutions

Ludwig-Maximilians-Universität München

Charité - Universitätsmedizin Berlin

University of Cologne

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study